Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman, I; Ribot, C; Smith, Ret al.
2000 • In Journal of Clinical Endocrinology and Metabolism, 85 (5), p. 1895-900
[en] Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter. At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in the 2.5-mg group, compared with no change with placebo. Efficacy was similar in women who were less than 5 yr and more than 5 yr postmenopausal. At 24 months, risedronate (5 mg) had also increased BMD at the femoral neck and trochanter, whereas BMD decreased in the placebo group. BMD increases were seen at all three sites with risedronate (5 mg) after only 6 months of therapy. Risedronate was well tolerated; upper gastrointestinal adverse events were similar to placebo. We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause.
Disciplines :
General & internal medicine
Author, co-author :
Fogelman, I
Ribot, C
Smith, R
Ethgen, D
Sod, E
REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Publication date :
2000
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Riggs B.L., Melton III L.J. (1992) The prevention and treatment of osteoporosis. N Engl J Med , published erratum appears in 1993 N EngI J Med. 328:65; 327:620-627.
Ross P.D., Davis J.W., Vogel J.M., Wasnich R.D. (1990) A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 46:149-161.
Melton III L.J., Atkinson E.J., O'Fallon W.M., Wahner H.W., Riggs B.L. (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227-1233.
Kanis J.A. (1993) What constitutes evidence for drug efficacy in osteoporosis?. Drugs Aging 3:391-399.
Cummings S.R., Kelsey J.L., Nevitt M.C., O'Dowd K.J. (1985) Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7:178-208.
Dolan P., Torgerson D.J. (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611-617.
Physician's guide to prevention and treatment of osteoporosis, Belle Mead, New Jersey: Excerpta Medica; 1998.
Lufkin E.G., Wahner H.W., O'Fallon W.M. (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann intern Med 117:1-9.
Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. (1995) Estrogen replacement therapy and fractures in older women. Ann Intern Med , Study of Osteoporotic Fractures Research Group; 122:9-1216.
Ravnikar V.A. (1987) Compliance with hormone therapy. Am J Obstet Gynecol 156:1332-1334.
Barrett-Connor E. (1995) Prevalence, initiation, and continuation of hormone replacement therapy. J Womens Health 4:143-148.
Ettinger B., Black D.M., Mitlak B.H. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637-645.
Delmas P.D., Bjarnason N.H., Mitlak B.H. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
Francis R.M. (1997) Bisphosphonates in the treatment of osteoporosis in 1997: A review. Curr Ther Res 58:656-678.
(1996) Clinical practice guidelines for the diagnosis and management of osteoporosis. Can Med Assoc J 155:1113-1133.
Hosking D., Chilvers C.E., Christiansen C. (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med , Early Postmenopausal Intervention Cohort Study Group; 338:485-492.
Fogelman I., Blake G. (1998) Early postmenopausal bone loss and intermittent cyclical etidronate therapy. Rev Contemp Pharmacother 9:245-254.
McClung M., Clemmesen B., Daifotis A. (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med , Alendronate Osteoporosis Prevention Study Group; 128:253-261.
Harris S.T., Watts N.B., Jackson R.D. (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567.
Watts N.B., Harris S.T., Genant H.K. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
Liberman U.A., Weiss S.R., Bröll J. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
Siris E.S., Chines A.A., Altman R.D. (1998) Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
Singer F.R., Clemens T.L., Eusebio R.A., Bekker P.J. (1998) Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83:1906-1910.
Mortensen L., Charles P., Bekker P.J., DiGennaro J., Johnston C.C. Jr. (1998) Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396-402.
Stanley-Cohen S., Levy R.M., Keller M. (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:3209-3218.
Clemmesen B., Ravn P., Zegels B., Taquet A.N., Christiansen C., Reginster J.Y. (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7:488-495.
Genant H.K., Grampp S., Gluer C.C. (1994) Universal standardization for dual x-ray absorptiometry: Patient and phantom cross-calibration results. J Bone Miner Res 9:1503-1514.
Faulkner K.G., McClung M.R. (1995) Quality control of DXA instruments in multicenter trials. Osteoporos Int 5:218-227.
Kiel D. (1995) Assessing vertebral fractures. J Bone Miner Res , National Osteoporosis Foundation Working Group on Vertebral Fractures [published erratum appears in 1995 J Bone Miner Res. 10:1605]; 10:518-523.
Melton III L.J., Lane A.W., Cooper C., Eastell R., O'Fallon W.M., Riggs B.L. (1993) Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113-119.
Johnston C.C. Jr., Bekker P.J., Van den Ouweland F. (1995) Risedronate prevention of bone loss in early postmenopausal women. Calcif Tissue Int 56:494.
McClung M.R., Bensen W., Bolognese M.A. (1997) Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low bone mass. J Bone Miner Res 12.
Devogelaer J.P., Broll H., Correa-Rotter R. (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150.
Tucci J.R., Tonino R.P., Emkey R.D. (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501.
Ettinger B., Pressman A., Schein J., Chart J., Silver P., Connolly N. (1998) Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 4:488-492.
De Groen P.C., Lubbe D.F., Hirsch L.J. (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
Maconi G., Porro G.B. (1995) Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 90:1889-1890.